| Pharmacotherapy of urolithiasis: evidence from clinical trials. | |
| | |
MedLine Citation:
|
PMID: 20927039 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Urolithiasis is a worldwide problem with significant health and economic burdens. Medical therapy that alters the course of stone disease has enormous medical and financial impact. Urolithiasis is a final manifestation of a broad range of etiologies and pathogenesis. The modest progress in understanding the pathophysiology has hampered successful development of targeted therapy. Current regimens are based mostly on rational alteration of urinary biochemistry and physical chemistry to lower the risk of precipitation. In terms of pharmacotherapy, there are drugs to successfully improve hypercalciuria, hypocitraturia, aciduria, hyperuricosuria, and hypercystinuria. These agents have been proven to be effective in randomized controlled trials in improving urinary biochemical and physicochemical risk factors, as well as clinical outcomes. Although our current regimens have clearly improved the management and lives of stone formers, there are still clearly identifiable immense voids in the knowledge of pathophysiology of stone disease that can be filled with combined basic science and clinical studies. |
| | |
Authors:
|
Orson W Moe; Margaret S Pearle; Khashayar Sakhaee |
Related Documents
:
|
20439879 - Why pharmacists belong in the medical home. 14994109 - A systematic review of medical therapy for anal fissure. 10950029 - Fecal incontinence: a practical approach to evaluation and treatment. 4059129 - Home intravenous antibiotic therapy. a practical management approach for the 1980s. 16643579 - Medications associated with probable medication overuse headache reported in a tertiary... 21521709 - Managing unused pharmaceuticals in a hospice setting: a pilot study. 16053939 - London bombings july 2005: the immediate pre-hospital medical response. 10401359 - The use of over-the-counter medications by transplant recipients: a guideline. 1166989 - Lithium salts: 1970-1975. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review Date: 2010-10-06 |
Journal Detail:
|
Title: Kidney international Volume: 79 ISSN: 1523-1755 ISO Abbreviation: Kidney Int. Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-01-31 Completed Date: 2011-05-06 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 0323470 Medline TA: Kidney Int Country: United States |
Other Details:
|
Languages: eng Pagination: 385-92 Citation Subset: IM |
Affiliation:
|
University of Texas Southwestern Medical Center, Dallas, Texas 75380, USA. orson.moe@utsouthwestern.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Citric Acid
/
urine Cystinuria / drug therapy Humans Hypercalciuria / drug therapy Hyperoxaluria / drug therapy Randomized Controlled Trials as Topic Urinary Calculi / chemistry Urolithiasis / drug therapy*, urine |
| Grant Support | |
ID/Acronym/Agency:
|
DK079328/DK/NIDDK NIH HHS; DK081432/DK/NIDDK NIH HHS; DK081523/DK/NIDDK NIH HHS; DK20543/DK/NIDDK NIH HHS; P01 DK020543-31/DK/NIDDK NIH HHS; P30 DK079328-04/DK/NIDDK NIH HHS; R01 DK081423-02/DK/NIDDK NIH HHS; R01 DK081523-02/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
77-92-9/Citric Acid |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis.
Next Document: Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality.